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Aim: To assess for the ﬁ  rst time the vasodilatory effect of testosterone in the human pulmonary 
circulation utilizing both isolated human pulmonary arteries and isolated perfused human lungs. 
In addition, a secondary aim was to determine whether there was any difference in the response 
to testosterone dependant upon gender.
Methods: Isolated human pulmonary arteries were studied by wire myography. Vessels 
were preconstricted with U46619 (1 nM–1 μM) prior to exposing them to either testosterone 
(1 nM–100 μM) or ethanol vehicle (0.1%). Isolated lungs were studied in a ventilated and 
perfused model. They were exposed to KCl (100 mM), prior to the addition of either testosterone 
(1 nM–100 μM) or ethanol vehicle (0.1%).
Results: Testosterone caused signiﬁ  cant vasodilatation in all preparations, but a greater response 
to testosterone was observed in the isolated perfused lungs, 24.9 ± 2.2% at the 100 μM dose of 
testosterone in the isolated pulmonary arteries compared to 100 ± 13.6% at the 100 μM dose 
in the isolated perfused lungs. No signiﬁ  cant differences in the response to testosterone were 
observed between sexes.
Conclusion: Testosterone is an efﬁ  cacious vasodilator in the human pulmonary vasculature and 
this is not modulated by patient sex. This vasodilator action suggests that testosterone therapy 
may be beneﬁ  cial to male patients with pulmonary arterial hypertension.
Keywords: human, pulmonary circulation, pulmonary hypertension, sex hormone, testosterone, 
vasodilation
Introduction
Sex hormones exert their biological effects primarily through genomic mechanisms. 
However both female and male sex hormones also elicit nongenomic effects. Estrogens 
such as 17β-estradiol act as vasodilators through the release of nitric oxide from the 
vascular endothelium and also by relaxing vascular smooth muscle cells directly 
(Gonzales et al 2001). In contrast, testosterone and progesterone have no endothelial 
effects in vitro, but have been shown to cause vasodilatation by direct interaction with 
ion channels within the vascular smooth muscle cell membrane (Li et al 2001; Jones 
et al 2002). In this respect we have recently reported that testosterone acts like the 
calcium channel blocker nifedipine by inhibiting the L-type voltage-gated calcium 
channels (VGCCs) (Scragg et al 2004; Hall et al 2006). Clinical trials in patients have 
shown that testosterone prolongs the time to myocardial ischemia in patients with 
chronic stable angina (English et al 2000a) and improves exercise capacity in men with 
heart failure (Pugh et al 2004), effects which may be a consequence of vasodilatation 
induced by this cellular action.
In the pulmonary circulation, pulmonary arterial hypertension (PAH) of which 
idiopathic pulmonary hypertension is a subgroup, previously known as primary 
pulmonary hypertension, is three times more common in females compared with 
males (Dalonzo et al 1991). PAH is a rare disease of the pulmonary vasculature Vascular Health and Risk Management 2008:4(6) 1460
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deﬁ  ned as a mean pulmonary artery pressure 25 mmHg 
at rest or 30 mmHg with exercise (Gibbs et al 2001). The 
pathogenesis of the development of PAH is proposed to be 
multifactorial, involving genetic factors such as the trans-
forming growth factor beta (TGF-β) superfamily of genes, 
vasoactive mediators such as prostacyclin, nitric oxide 
(NO), serotonin, angiotensin II and endothelin 1 (ET-1), as 
well as cytokines and other growth factors such as vascular 
endothelial growth factor (VEGF) (reviewed in Runo and 
Loyd 2003). These conspire to induce vascular remodeling 
and vasoconstriction and the characteristic pathological 
changes, including medial hypertrophy of the muscular 
pulmonary arteries, concentric laminar intimal ﬁ  brosis, 
plexiform lesions, ﬁ  brinoid degeneration and thrombotic 
lesions (Wagenvoort 1980; Bjornsson and Edwards 1985; 
Pietra et al 1989).
Testosterone has been shown to induce vasodilatation 
in the rat pulmonary vasculature (English et al 2001; 
Jones et al 2002), with a mechanism proposed to involve 
a calcium antagonist action (Jones et al 2002). This study 
was therefore carried out to assess for the ﬁ  rst time, the 
effects of testosterone in the human pulmonary circulation 
utilizing both isolated human pulmonary arteries and isolated 
perfused human lungs. In addition, a secondary aim was to 
determine whether there was any difference in the response 
to testosterone between males and females.
Methods
This study was carried out in accordance with the declaration 
of Helsinki (2000) of the World Medical Association and 
full approval to undertake the study was obtained from the 
relevant local ethics committee. All patients gave written 
informed consent. Lung samples were obtained from patients 
(n = 25, age = 62 [3] years) undergoing elective lobe or lung 
resection at Northern General Hospital, Shefﬁ  eld and Castle 
Hill Hospital, Hull.
Isolated human pulmonary arteries
Intralobar pulmonary arteries were carefully dissected from 
healthy areas of lung sections obtained from male (n = 7 age 
= 65 [3] years) and female patients (n = 6, age = 56 [7] years). 
Care was taken to avoid damage to the vessels’ smooth mus-
cle layer or endothelium. Vessels were then mounted on two 
40 μm stainless steel wires between the jaws of an automated 
small vessel myograph (Cambustion Ltd, Cambridge, UK). 
The myograph bath contained 7 ml physiological saline solu-
tion (PSS) warmed to 37 °C and bubbled with 95% O2/5% 
CO2 to maintain a pH of 7.4. Vessels were then loaded to a 
tension equivalent to a transmural pressure of 17.5 mmHg, 
the normal in vivo pressure.
After loading, the intralobar pulmonary arteries 
(n = 32, mean internal diameter = 546 [45] μm) studied in 
the Cambustion myograph were then allowed to equilibrate 
before exposure to 1 μM U46619. U46619 is a prostaglandin 
analogue, acting at VGCCs and store operated calcium 
channels (SOCCs), causing vasoconstriction. The maxi-
mum contraction was then recorded before the addition of 
ACh (1 μM), which causes endothelium dependant vaso-
dilatation. Endothelial integrity was conﬁ  rmed by 10% 
vasodilatation response to ACh. The vessels were then 
washed by changing the PSS and left to re-equilibrate back 
to their original baseline tension. Vessels were then exposed 
to cumulative doses of U46619 (1 nM–1 μM) and after 
reaching maximum contraction they were exposed to either 
cumulative doses of testosterone (1 nM–100 μM) or ethanol 
vehicle (maximum concentration = 0.1%). The addition of 
ethanol vehicle was carried out to ensure that the ethanol 
itself, in which the testosterone is dissolved, did not cause 
vasodilatation.
After a maximal dilatation had been observed vessels 
were washed by changing the PSS in the myograph bath 
and allowed to return to baseline tension. The vessels 
were subsequently exposed to cumulative doses of 
U46619 (1 nM–1 μM), and cumulative concentrations of the 
alternative agent, either ethanol vehicle or testosterone.
Isolated perfused human lung model
The ex vivo saline perfused human lung system (Bennett 
et al 2004) is shown in Figure 1. Lung samples (n = 12) were 
obtained from male (n = 6, age = 62 [7] years) and female 
(n = 6, age = 66 [4] years) patients and suspended from a force 
transducer (strain gauge) inside the collection reservoir (Sorin 
Biomedica, Quedgeley, Gloucester, UK). The pulmonary 
arterial and bronchial circulations were cannulated using the 
largest cannulae possible. The bronchial cannula was connected 
to a piston ventilator (Harvard Apparatus Ltd, Edenbridge, 
Kent, UK) and was ventilated with room air at 10 breaths/min 
and tidal volume 100–300 ml. The pulmonary artery cannula 
was connected to a perfusion circuit (Cobe Laboratories, 
Quedgeley, Gloucester, UK) which had been primed with 
1 liter oxygenated Krebs bicarbonate solution. The perfus-
ate was circulated to the pulmonary arteries from a second 
reservoir (Baxter Healthcare, Compton, Berkshire, UK) 
via a peristaltic roller pump 100–300 ml/min (Terumo UK, 
Knowsley, Merseyside, UK). The temperature was maintained 
at 36–38 °C by a heat exchanger (Sorin Biomedica, California, Vascular Health and Risk Management 2008:4(6) 1461
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USA) and pH at 7.4 via a pH meter (Thermo Russell, Fife, 
UK), which activated the supply of additional CO2 into the 
perfusate via a valve control, when the pH was greater than 
7.4. The perfusion pressure, airway pressure and weight were 
continually recorded.
Once stable baseline airway and perfusion pressures were 
obtained the lungs were exposed to KCl (100 mM) and the 
maximum contraction was recorded. Cumulative additions 
of either testosterone (1 nM–100 μM) or ethanol vehicle 
(maximum concentration = 0.1%) were then performed. The 
system was then washed with 2 liters of fresh Krebs solution 
before the preparation was re-exposed to KCl (100 mM) and 
the alternative agent added.
Materials and reagents
Krebs bicarbonate solution consisted of 113.8 mM NaCl, 
4.7 mM KCl, 1.2 mM MgSO4, 25 mM NaHCO3, 1.2 mM 
KH2PO4, 11.4 mM glucose and 2.4 mM CaCl2 dissolved in 
distilled water. PSS consisted of 120 mM NaCl, 4.7 mM KCl, 
1.17 mM MgSO4, 25 mM NaHCO3, 1.18 mM KH2PO4, 
5.5 mM glucose, 2.5 mM CaCl2, and 26.9 μM EDTA 
dissolved in distilled water. All other chemicals were 
obtained from Sigma, Poole, Dorset, UK. Testosterone and 
U46619 were dissolved in ethanol and ACh and KCl were 
dissolved in distilled water.
Statistical analysis
All valves are expressed as mean (SEM). Initial analysis 
examining whether there was a statistical difference between 
the response of vessels to testosterone versus ethanol, was 
made by Student’s paired or unpaired t-test for parametric 
data. Subsequent analysis was then made between responses to 
testosterone between male and female preparations. In this set 
of analyses the dilator responses to testosterone are expressed 
as percentage reversal of the pre-contractile tone less the 
negligible vasoactive action of ethanol vehicle (always 10% 
contraction/dilatation) and compared using ANOVA. In all 
cases P  0.05 was considered statistically signiﬁ  cant.
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Figure 1 Perfusion-ventilation circuit for ex vivo isolated lung model. This diagram shows the lung attached via a cannula to the ventilator, seen on the left. A further cannula 
attaches the lung to the perfusion circuit, whereby oxygenated Krebs solution is passed from the reservoir, by a roller pump, via a heat exchanger to the lung. The pH of the 
Krebs solution is monitored and extra carbon dioxide (CO2) is added as required.   The pH, weight, perfusion pressure, temperature and airway pressure are all measured and 
displayed on a computer screen, seen here on the right.Vascular Health and Risk Management 2008:4(6) 1462
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Results
Isolated human pulmonary arteries
The basal characteristics of the pulmonary vessels studied in the 
Cambustion myograph is displayed in Table 1. No signiﬁ  cant 
differences were observed in the patient age, vessel size, baseline 
tension or responsiveness between groups of preparations. 
Subsequent dilatory responses were consequently standardized 
by expression as percentage reversal of precontractile tone.
Effect of testosterone
The isolated human pulmonary arteries showed signiﬁ  cant 
vasodilation compared to ethanol, reaching statistical 
signiﬁ  cance at 30 μM and 100 μM (Figure 2).
Effect of gender
Pulmonary arteries obtained from male and female patients 
showed no signiﬁ  cant difference in the magnitude of the 
response to testosterone (Figure 3).
Isolated perfused human lungs
The basal characteristics of the isolated perfused human 
lung preparations are displayed in Table 2. No signiﬁ  cant 
differences were observed in the age, baseline pressure or 
responsiveness between groups of preparations.
Effect of testosterone
The vasodilator response to testosterone in the isolated per-
fused human lung preparations is displayed in Figure 4. This 
reached statistical signiﬁ  cance at 100 μM. The response to 
testosterone was larger than that observed in the isolated 
vessels, as observed by comparison between Figures 2 
and 4 (maximum change in tension in the isolated human 
pulmonary arteries −24.9 ± 2.2% versus 100 ± 13.6%, in 
isolated perused human lung samples, P  0.0001).
Effect of gender
Isolated perfused human lung samples obtained from male 
and female patients showed no signiﬁ  cant difference in the 
magnitude of the response to testosterone (Figure 5).
Discussion
The results of this study demonstrate for the ﬁ  rst time that 
testosterone acts as an efﬁ  cacious vasodilator in the human 
pulmonary circulation. Dilatation was observed follow-
ing exposure to testosterone in isolated human pulmonary 
arteries and in isolated ventilated and perfused human lungs. 
Signiﬁ  cant dilatation was observed at supraphysiological 
concentrations (normal range 8–30 nmol/1), although marked 
vasodilatation was observed in all preparations at micromolar 
concentrations.
No signiﬁ  cant difference in vasodilatation to testosterone 
was observed in pulmonary arteries obtained from male 
patients compared to those obtained from female patients 
(Figure 3). This ﬁ  nding was also seen in the isolated perfused 
lungs (Figure 5). The isolated perfused human lung studies, is 
the most representative of the in vivo situation, as the model 
contains both resistance vessels 500 μm in diameter and 
pulmonary veins. These resistance vessels are impossible to 
dissect for myography studies, however they are the main 
vessels governing pulmonary vascular tone. The pulmonary 
veins are also important as the venous circulation is sensitive 
to the vasodilator action of testosterone (Rowell et al 2003). 
This lack of a signiﬁ  cant difference dependant upon gender in 
the isolated pulmonary vessels and the isolated perfused human 
lung studies is in contrast to the situation in the pulmonary 
vasculature of the rat where testosterone is reported to exhibit 
signiﬁ  cantly greater dilatation in isolated pulmonary arteries 
obtained from males (English et al 2001). This may represent 
species variation in the effects of testosterone. Alternatively it 
may be a consequence of the difference in age. The tissue used 
in the present study was obtained from elderly patients, whereas 
the rat vessels were obtained from young sexually mature ani-
mals. We have previously reported that aging is associated 
with a decline in the vasodilator activity of testosterone in the 
male coronary circulation (English et al 2000b).
These data demonstrate that testosterone is an efﬁ  cacious 
dilatory agent within the whole of the human pulmonary 
vasculature. Furthermore, they provide an insight into the 
Table 1 The vessel characteristics used in this set of experiments, detailing the number of patients and their mean age, as well as the 
mean internal diameter of those vessels and their response to the vasocontractile agent U46619 and vasodilator agent acetylcholine 
(ACh).   Values expressed as mean (SEM)
Number 
of vessels
Mean internal 
diameter (μm)
Mean patient 
age (years)
Number 
of patients
Mean contraction
to 10 μm U46619 (mN/mm)
Mean dilatation to 
10 μm Ach (% Relaxation)
Pulmonary
arteries – Male
18 550 (73) 65 (3) 7 2.52 (0.36) −14.6 (4.7)
Pulmonary
arteries – Female
14 541 (42) 56 (7) 6 2.38 (0.39) −9.5 (3.5)Vascular Health and Risk Management 2008:4(6) 1463
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Figure 2 Concentration-response curve depicting the dilator response to testosterone (1nm–100 μM) in isolated human pulmonary arteries, maximally pre-constricted with 
U46619 (1 μM), studied in the Cambustion myograph. Data are expressed as mean change in active tension ± SEM. Circles (z) represent vessels exposed to testosterone 
(n = 32), whilst triangles (Δ) represent vessels exposed to ethanol (n = 32). Signiﬁ  cant vasodilatation compared to ethanol is seen at the last two doses of testosterone, 30 μm 
and 100 μm.
Note: *P  0.05 represents signiﬁ  cant vasodilatation from ethanol vehicle via Student’s t-test, following ANOVA.
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Figure 3 Concentration-response curve depicting the dilator response to testosterone (1nm–100 μM) in isolated pulmonary arteries, studied in the Cambustion myograph 
displayed as preparations obtained from male ( ) (n = 18) and female (◊) (n = 14) patients, maximally pre-constricted with U46619 (1 μM). Data are expressed as mean 
change in active tension (corrected for the negligible vasoactive effect of ethanol vehicle) ± SEM. No signiﬁ  cant difference was seen between vessels from male and female 
vessels on the response to testosterone.Vascular Health and Risk Management 2008:4(6) 1464
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vasodilator mechanism of action of testosterone within 
the human pulmonary vascular bed. It would appear that 
the mechanism of action is nongenomic in nature, since 
vasodilatation was observed within minutes of application of 
the hormone (23 ± 3 minutes in the IPHL model), rather then 
a prolonged time interval, which would be expected if binding 
to the androgen receptor and alteration of protein synthesis 
was occurring. This is consistent with previous studies under-
taken in isolated rat pulmonary arteries, which suggest that 
testosterone elicits pulmonary vasodilatation via inhibition 
of voltage gated calcium channels (Jones et al 2002).
The results of the present study also support this mechanism 
of action in humans: The effect of testosterone in the isolated 
pulmonary arteries clearly depends upon the precontractile 
agonist used, with signiﬁ  cantly more dilatation being observed 
in the IPHL experiments preconstricted with KCl compared 
to pulmonary vessels preconstricted with U46619. It has been 
shown that KCl-induced vasoconstriction in similar isolated 
human pulmonary arteries occurs exclusively via extracellular 
calcium entry through VGCCs, whilst exposure to U46619 
results in extracellular calcium entry through VGCC and also 
SOCCs, in approximately equal amounts (Hall et al 2004). 
Consequently if testosterone is only inhibiting the VGCCs 
and not SOCCs, as has been proposed in the rat pulmonary 
circulation (Jones et al 2002), the resulting dilatation in ves-
sels preconstricted with U46619 would be expected to be 
approximately 50% less than in those preconstricted with 
KCl. This was the case in these experiments, with Figure 2 
showing a change in tension of 24.9 ± 2.2% at the 100 μM dose 
of testosterone in the isolated pulmonary arteries compared to 
Table 2 The basal characteristics of the isolated human lung preparations.   Values expressed as mean (SEM)
Number
of lungs
Number
of patients
Mean patient age (years) Baseline pressure (mmHg) Mean contraction to 100 mM 
KCl (mmHg)
Isolated perfused
lung – Male
6 6 62 (7) 17.4 (0.4) 13.0 (5.7)
Isolated perfused
lung – Female
6 6 66 (4) 17.8 (0.4) 15.3 (4.2)
ANOVA
P < 0.005
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Figure 4 Concentration-response curve depicting the dilator response to testosterone (1nm–100 μM) in isolated perfused human lung maximally preconstricted with KCL 
(100 mM). Data are expressed as mean change in active ± SEM. Circles (z) represent vessels exposed to testosterone (n = 12), whilst triangles (Δ) represent vessels exposed 
to ethanol (n = 12).
Notes: *P  0.05 represents signiﬁ  cant vasodilatation from ethanol vehicle via Student’s t-test, following ANOVA.Vascular Health and Risk Management 2008:4(6) 1465
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100 ± 13.6% at the 100 μM dose of testosterone in the isolated 
perfused human lung studies (Figure 4).
This vasodilator/calcium antagonistic activity of testoster-
one may allude to a new therapeutic opportunity for men with 
pulmonary hypertension. Calcium channel blockers, such as 
amlodipine, diltiazem, and nifedipine, have been used success-
fully in the treatment of pulmonary hypertension (Rubin et al 
1983; Rich et al 1992; Woodmansey et al 1996) and as we 
have recently reported that testosterone acts like the calcium 
channel blocher nifedipine by inhibiting the L-type voltage-
gated calcium channels (VGCCs) (Scragg et al 2004; Hall et al 
2006), therefore testosterone therapy may also be a potential 
treatment for male patients with pulmonary hypertension. The 
concentrations of testosterone required to produce vasodilata-
tion in these in vitro preparations were supraphysiological, and 
therefore the applicability to patients may be questionable. 
However it has been shown that testosterone acts at physiologi-
cal concentrations at the cell level (Scragg et al 2004; Hall et al 
2006) and positive results have been seen with testosterone 
therapy in patients with angina (English et al 2000a) and heart 
failure (Pugh et al 2004; Malkin et al 2009), despite a similar 
discrepancy in the concentration required to induce dilatation 
in isolated rat coronary arteries (Jones et al 2004). Furthermore 
there is evidence that testosterone may be actively absorbed 
by the capillaries leading to much higher concentrations of 
testosterone at the capillary membrane than is measured by 
serum samples (Porto et al 1995). This discrepancy between 
the concentrations of chemicals required to produce effects in 
vivo and in vitro is also seen with others agents, for example 
the potassium channel opener chromakalin. This reduces 
systolic arterial pressure and systemic vascular resistance in 
vivo at concentrations of 2–3 × 10−8 M (Thomas et al 1990). In 
vitro these vasodilator effects are seen at 1 × 10−6 M to 1 × 10−5 
M (Bray et al 1991).
In summary, testosterone is an efﬁ  cacious vasodilator in 
the human pulmonary vasculature and this is not modulated by 
patient sex. This vasodilator action suggests that testosterone 
therapy may be beneﬁ  cial to male patients with PAH, as 
reported in men with coronary artery disease (English et al 
2000a) or congestive heart failure (Pugh et al 2004; Malkin 
et al 2009). Testosterone therapy unfortunately could not be 
offered to female patients, due to the secondary male sexual 
characteristics that may develop as a result of treatment. The 
mechanism of the vasodilator action of testosterone in rat 
pulmonary arteries is reported to be via calcium antagonism, 
specifically VGCCs (Jones et al 2002) however further 
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Figure 5 Concentration-response curve depicting the dilator response to testosterone (1nm–100 μM) in isolated perfused human lung experiments, displayed as preparations 
obtained from male ( ) (n = 6) and female (◊) (n = 6) patients, maximally preconstricted with KCl (100 mM). Data are expressed as mean change in active tension (corrected for 
the negligible vasoactive effect of ethanol vehicle) ± SEM. No signiﬁ  cant difference was seen between vessels from male and female vessels on the response to testosterone.Vascular Health and Risk Management 2008:4(6) 1466
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experiments are required to conﬁ  rm the mechanism in the 
human pulmonary circulation.
Acknowledgments
This project was funded by a project grant from Heart 
Research UK, formerly the National Heart Research Fund. 
The authors would like to thank Mr D Hopkinson, Mr S Billing, 
Mr G Rocco and Mr R Vaughan, consultant cardio-thoracic 
surgeons at the Northern General Hospital, Shefﬁ  eld, UK, for 
kindly providing us access to their patients, and Dr Steve Gill, 
Dr Jane Wagstaff and Miss Stephanie Clark for their assistance 
in the identiﬁ  cation and consenting of suitable patients and in 
collecting the resected tissue. The authors would like to thank 
Dr SK Suvarna, consultant pathologist at the Northern General 
Hospital, Shefﬁ  eld, UK, for his advice and expertise in provid-
ing us with macroscopically normal lung tissue. The authors 
declare no competing or conﬂ  ict of interest in this work.
References
Bennett RT, Jones RD, Morice AH, et al. 2004. Vasoconstrictive effects of 
endothelin-1, endothelin-3, and urotensin II in isolated perfused human 
lungs and isolated human pulmonary arteries. Thorax, 59:401–7.
Bjornsson J, Edwards WD. 1985. Primary Pulmonary-Hypertension – a 
Histopathologic Study of 80 Cases. Mayo Clin Proc, 60:16–25.
Bray K, Quast, U. 1991. Differences in K+ channels opened by cromokalin, 
acetylcholine and Substance P in rat aorta and porcine coronary artery. 
Br J Pharmacol, 102:585–94.
Dalonzo GE, Barst RJ, Ayres SM, et al. 1991. Survival in patients with 
primary pulmonary-hypertension – Results from a National Prospective 
Registry. Ann Intern Med, 115:343–9.
English KM, Steeds RP, Jones TH, et al. 2000a. Low-dose transdermal 
testosterone therapy improves angina threshold in men with chronic 
stable angina – A randomized, double-blind, placebo-controlled study. 
Circulation, 102:1906–11.
English KM, Jones RD, Jones TH, et al. 2000b. Aging reduces the 
responsiveness of coronary arteries from male Wistar rats to the 
vasodilatory action of testosterone. Clin Sci, 99:77–82.
English KM, Jones RD, Jones TH, et al. 2001. Gender differences in the 
vasomotor effects of different steroid hormones in rat pulmonary and 
coronary arteries. Horm Metab Res, 33:645–52.
Gibbs JSR, Higenbottam TW, Black C, et al. 2001. Recommendations 
on the management of pulmonary hypertension in clinical practice. 
Heart, 86:I1–I13.
Gonzales RJ, Walker BR, Kanagy NL. 2001. 17 beta-Estradiol increases 
nitric oxide-dependent dilation in rat pulmonary arteries and thoracic 
aorta. Am J Physiol Lung Cell Mol Physiol, 280:L555–4.
Hall J, Jones RD, Vaughan R, et al. 2004. Mechanisms of agonist-induced 
vasoconstriction in isolated human pulmonary arteries. British 
Pharmacological Society, 2:034.
Hall J, Jones RD, Jones TH, et al. 2006. Selective inhibition of L-type 
Ca2+ channels in A7r5 cells by physiological levels of testosterone. 
Endocrinology, 147:2675–80.
Jones RD, English KM, Pugh PJ, et al. 2002. Pulmonary vasodilatory action 
of testosterone: Evidence of a calcium antagonistic action. J Cardiovasc 
Pharmacol, 39:814–23.
Jones RD, English KM, Jones TH, et al. 2004. Testosterone-induced 
coronary vasodilatation occurs via a non-genomic mechanism: evidence 
of a direct calcium antagonism action. Clin Sci, 107:149–58.
Li HF, Zheng TZ, Li W, et al. 2001. Effect of progesterone on the contractile 
response of isolated pulmonary artery in rabbits. Can J Physiol 
Pharmacol, 79:545–50.
Malkin CJ, Jones TH, Channer KS. 2009. Testosterone in chronic heart 
failure. Front Horm Res, 37:183–96.
Pietra GG, Edwards WD, Kay JM, et al. 1989. Histopathology of primary 
pulmonary hypertension. A qualitative and quantitative study of 
pulmonary blood vessels from 58 patients in the National Heart, 
Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. 
Circulation, 80:1198–206.
Porto CS, Lazari MFM, Abreu LC, et al. 1995. Receptors for androgen 
binding proteins: Internalisation and intracellular signalling. J Steroid 
Biochem Mol Biol, 53:561–5.
Pugh PJ, Jones RD, West JN, et al. 2004. Testosterone treatment for men 
with chronic heart failure. Heart, 90:446–7.
Rich S, Kaufmann E, Levy PS. 1992. The effect of high doses of calcium-channel 
blockers on survival in primary pulmonary hypertension. N Engl J Med, 
327:76–81.
Rowell KO, Jones RD, Pugh PJ, et al. 2003. Testosterone is an efﬁ  cacious 
vasodilator in isolated human pulmonary and mesenteric arteries and 
veins. Heart, 89:A30.
Rubin LJ, Nicod P, Hillis LD, et al. 1983. Treatment of primary pulmo-
nary hypertension with nifedipine. A hemodynamic and scintigraphic 
evaluation. Ann Intern Med, 99:433–8.
Runo JR, Loyd JE. 2003. Primary pulmonary hypertension. Lancet, 
361:1533–44.
Scragg JL, Jones RD, Jones TH, et al. 2004. Testosterone is a potent inhibitor 
of L-type Ca2+ channels. Biochem Biophys Res Commun, 318:503–6.
Thomas P, Dixon MS, Winterton SJ, et al. 1990. Acute haemodynamic 
effects of cromakalin in patients with angina pectoris. Br J Clin 
Pharmacol, 29:325–31.
Wagenvoort CA. 1980. Lung biopsy specimens in the evaluation of 
pulmonary vascular disease. Chest, 77:614–25.
Woodmansey PA, Otoole L, Channer KS, et al. 1996. Acute pulmonary 
vasodilatory properties of amlodipine in humans with pulmonary 
hypertension. Heart, 75:171–3.